China Isotope & Radiation (HKG:1763) said the clinical trial application for Borofalan (10B) for Injection has been approved by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The drug was developed by the radiopharmaceuticals firm's unit, Shenzhen Zhonghe Headway Bio-Sci & Tech, to treat head and neck tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments